DK0792458T3 - Fremgangsmåder til hjælp ved diagnosen af Alzheimers sygdom ved måling af amyloid-betapeptid (x->41) og tau - Google Patents

Fremgangsmåder til hjælp ved diagnosen af Alzheimers sygdom ved måling af amyloid-betapeptid (x->41) og tau

Info

Publication number
DK0792458T3
DK0792458T3 DK95939892T DK95939892T DK0792458T3 DK 0792458 T3 DK0792458 T3 DK 0792458T3 DK 95939892 T DK95939892 T DK 95939892T DK 95939892 T DK95939892 T DK 95939892T DK 0792458 T3 DK0792458 T3 DK 0792458T3
Authority
DK
Denmark
Prior art keywords
alzheimer
diagnosis
disease
tau
aid
Prior art date
Application number
DK95939892T
Other languages
English (en)
Inventor
Carmen Vigo-Pelfrey
Peter A Seubert
Dale B Schenk
Robin Barbour
Original Assignee
Elan Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26991508&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0792458(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/339,141 external-priority patent/US6114133A/en
Application filed by Elan Pharm Inc filed Critical Elan Pharm Inc
Application granted granted Critical
Publication of DK0792458T3 publication Critical patent/DK0792458T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/811—Test for named disease, body condition or organ function

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Neurosurgery (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK95939892T 1994-11-14 1995-11-13 Fremgangsmåder til hjælp ved diagnosen af Alzheimers sygdom ved måling af amyloid-betapeptid (x->41) og tau DK0792458T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/339,141 US6114133A (en) 1994-11-14 1994-11-14 Methods for aiding in the diagnosis of Alzheimer's disease by measuring amyloid-β peptide (x-≧41)
US41900895A 1995-04-07 1995-04-07
PCT/US1995/014659 WO1996015452A1 (en) 1994-11-14 1995-11-13 METHODS FOR AIDING IN THE DIAGNOSIS OF ALZHEIMER'S DISEASE BY MEASURING AMYLOID-β PEPTIDE (X- ≥41) AND TAU

Publications (1)

Publication Number Publication Date
DK0792458T3 true DK0792458T3 (da) 2005-01-31

Family

ID=26991508

Family Applications (1)

Application Number Title Priority Date Filing Date
DK95939892T DK0792458T3 (da) 1994-11-14 1995-11-13 Fremgangsmåder til hjælp ved diagnosen af Alzheimers sygdom ved måling af amyloid-betapeptid (x->41) og tau

Country Status (11)

Country Link
US (4) US7427392B1 (da)
EP (2) EP1491889A3 (da)
JP (2) JP3634375B2 (da)
AT (1) ATE278957T1 (da)
AU (1) AU705907B2 (da)
CA (1) CA2205359C (da)
DE (1) DE69533623T2 (da)
DK (1) DK0792458T3 (da)
ES (1) ES2230551T3 (da)
PT (1) PT792458E (da)
WO (1) WO1996015452A1 (da)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6610493B1 (en) 1993-06-17 2003-08-26 Brigham And Women's Hospital Screening compounds for the ability to alter the production of amyloid-β peptide
US7427392B1 (en) 1994-11-14 2008-09-23 Elan Pharmaceuticals, Inc. Methods for aiding in the diagnosis of alzheimer's disease by measuring amyloid-β peptide (x-≧41) and tau
AU772151B2 (en) * 1998-09-08 2004-04-08 Innogenetics N.V. Tau as a marker for early CNS damage
EP1309341A2 (en) 2000-07-07 2003-05-14 Lars Lannfelt Prevention and treatment of alzheimer's disease
EP1975179A1 (en) * 2001-12-26 2008-10-01 Araclon Biotech, S.L. Polyclonal antibodies, preparation method thereof and use of same
US8360992B2 (en) 2002-04-19 2013-01-29 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
ES2246178B1 (es) * 2003-05-08 2007-03-01 Universidad De Zaragoza. Uso de anticuerpos para el tratamiento de enfermedades amiloideas.
SE0401601D0 (sv) * 2004-06-21 2004-06-21 Bioarctic Neuroscience Ab Protofibril specific antibodies and uses thereof
JP2008519988A (ja) * 2004-11-12 2008-06-12 ファイザー・インク アミロイド−ベータペプチドを測定する方法
WO2007044094A1 (en) * 2005-10-11 2007-04-19 Blanchette Rockefeller Neurosciences Institute Alzheimer's disease-specific alterations of the erk1/erk2 phosphorylation ratio as alzheimer's disease-specific molecular biomarkers (adsmb)
EP2325209A3 (en) 2006-03-23 2011-08-03 BioArtic Neuroscience AB Improved protofibril selective antibodies and the use thereof
EP1944314A1 (en) * 2007-01-11 2008-07-16 Philipps-Universität Marburg Diagnosis of Alzheimer's disease and other neurodementing disorders
DK2104682T3 (da) 2007-01-11 2017-01-16 Michael Bacher Diagnose og behandling af alzheimer’s og andre demenssygdomme
EP2578692B1 (en) 2007-04-05 2016-06-08 The J. David Gladstone Institutes Agents that reduce neuronal overexcitation
EP2009445A1 (en) * 2007-06-29 2008-12-31 Institut Pasteur Use of a camelid single-domain antibody for detecting an oligomeric form of an amyloid beta peptide and its applications
EP2020602A1 (en) * 2007-08-02 2009-02-04 Araclon Biotech High sensitivty immunoassays and kits for the determination of peptides and proteins of biological interest
WO2010099199A1 (en) * 2009-02-24 2010-09-02 Gibbons Winton G Detection of complexes of tau and amyloid
US20100285108A1 (en) * 2009-03-18 2010-11-11 Ac Immune, S.A. Method for therapeutic use
UA107571C2 (xx) * 2009-04-03 2015-01-26 Фармацевтична композиція
EP2258398A1 (en) 2009-05-26 2010-12-08 Araclón Biotech, S. L. Albumin-amyloid peptide conjugates and uses thereof
US20140302532A1 (en) 2011-04-12 2014-10-09 Quanterix Corporation Methods of determining a treatment protocol for and/or a prognosis of a patient's recovery from a brain injury
DK2579042T3 (da) 2011-10-04 2014-07-21 Affiris Ag Fremgangsmåde til at påvise Aß-specifikke antistoffer i en biologisk prøve
DE102011057021A1 (de) 2011-12-23 2013-06-27 Forschungszentrum Jülich GmbH Verfahren zur selektiven Quantifizierung von A-Beta-Aggregaten
JP5850374B2 (ja) 2012-01-27 2016-02-03 パナソニックヘルスケア株式会社 アルツハイマー病の診断補助方法、及び診断システム
AU2013243861A1 (en) 2012-04-05 2014-10-23 Ac Immune S.A. Humanized Tau antibody
HUE048780T2 (hu) 2012-08-16 2020-09-28 Ipierian Inc Tauopátia kezelésére szolgáló módszerek
US8980270B2 (en) 2013-01-18 2015-03-17 Ipierian, Inc. Methods of treating a tauopathy
ES2495266B8 (es) 2013-02-13 2015-11-12 Consejo Superior De Investigaciones Científicas (Csic) Uso de igf-1 como reactivo de diagnóstico y/o pronóstico precoz de la enfermedad de alzheimer
SG10201707855YA (en) 2013-03-13 2017-10-30 Prothena Biosciences Ltd Tau immunotherapy
CA2902910A1 (en) 2013-03-15 2014-09-25 Ac Immune S.A. Anti-tau antibodies and methods of use
KR20140128229A (ko) * 2013-04-26 2014-11-05 한국과학기술연구원 체내 단백질 응집체의 용해를 이용한 단백질의 비정상적인 응집 또는 미스폴딩과 관련된 질환 또는 질병을 진단하는 혈액진단키트
WO2015020523A1 (en) 2013-08-07 2015-02-12 Stichting Vu-Vumc Biomarkers for early diagnosis of alzheimer's disease
CN105939722A (zh) 2014-02-14 2016-09-14 伊皮埃里安股份有限公司 Tau肽，抗Tau抗体，及其使用方法
KR101890978B1 (ko) 2014-06-17 2018-08-24 서울대학교산학협력단 알츠하이머 질환 모델용 형질전환 돼지 및 이의 용도
CN106661103B (zh) 2014-07-10 2020-11-03 生命北极神经科学公司 改进的Aβ初原纤维结合抗体
CA3022673A1 (en) 2016-05-02 2017-11-09 Prothena Biosciences Limited Tau immunotherapy
BR112018072394A2 (pt) * 2016-05-02 2019-02-19 Prothena Biosciences Limited anticorpos que reconhecem a tau
EP3452508A1 (en) 2016-05-02 2019-03-13 Prothena Biosciences Limited Antibodies recognizing tau
IL270375B1 (en) 2017-05-02 2024-08-01 Prothena Biosciences Ltd Antibodies that recognize tau
AU2018355325A1 (en) 2017-10-25 2020-05-07 Ac Immune S.A. Compositions of phosphorylated tau peptides and uses thereof
WO2020098936A1 (fr) 2018-11-14 2020-05-22 Qynapse Procede de determination d'un modele de prediction, procede de prediction de l'evolution d'un k-uplet de marqueurs mk et dispositif associe
JOP20210211A1 (ar) 2019-02-08 2023-01-30 Janssen Pharmaceuticals Inc طريقة إعطاء دواء آمنة للقاح ببتيد تاو المفسفر
TW202100550A (zh) 2019-03-03 2021-01-01 愛爾蘭商普羅帝納生物科學公司 識別ｔａｕ之抗體
SG11202111770RA (en) 2019-04-24 2021-11-29 Janssen Pharmaceuticals Inc Heterologous administration of tau vaccines

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4271140A (en) 1978-01-23 1981-06-02 Baxter Travenol Laboratories, Inc. Method and composition for double receptor, specific binding assays
US4474892A (en) 1983-02-16 1984-10-02 Board Of Trustees Of The Leland Stanford Junior University Two-site immunoassays using monoclonal antibodies of different classes or subclasses and test kits for performing same
US4666829A (en) 1985-05-15 1987-05-19 University Of California Polypeptide marker for Alzheimer's disease and its use for diagnosis
JPS6267297A (ja) 1985-09-18 1987-03-26 Hitachi Ltd ポンプの軸受潤滑装置
JPH0779702B2 (ja) 1986-11-17 1995-08-30 サイオス ノバ インコーポレイテッド 組換えアルツハイマーアミロイドタンパク
US5223482A (en) * 1986-11-17 1993-06-29 Scios Nova Inc. Recombinant Alzheimer's protease inhibitory amyloid protein and method of use
US5220013A (en) * 1986-11-17 1993-06-15 Scios Nova Inc. DNA sequence useful for the detection of Alzheimer's disease
US5547841A (en) * 1987-10-08 1996-08-20 The Mclean Hospital Corporation In vitro method for screening for drugs that inhibit production or degradation of human A4-amyloid
US5262332A (en) * 1989-04-05 1993-11-16 Brigham And Women's Hospital Diagnostic method for Alzheimer's disease: examination of non-neural tissue
AU5525090A (en) 1989-04-14 1990-11-16 Research Foundation For Mental Hygiene, Inc. Monoclonal antibody to amyloid peptide
WO1990012871A1 (en) 1989-04-14 1990-11-01 Research Foundation For Mental Hygiene, Inc. Cerebrovascular amyloid protein-specific monoclonal antibody sv17-6e10
US5234814A (en) * 1989-06-01 1993-08-10 Du Pont Merck Pharmaceutical Company Diagnostic assay for alzheimer's disease
AU7121191A (en) 1990-02-26 1991-10-10 Albert Einstein College Of Medicine Of Yeshiva University Diagnostic assay for alzheimer's disease
US5213962A (en) * 1990-04-24 1993-05-25 The Regents Of The University Of California Purification, detection and methods of use of protease Nexin-2
US5387742A (en) * 1990-06-15 1995-02-07 Scios Nova Inc. Transgenic mice displaying the amyloid-forming pathology of alzheimer's disease
JPH04252956A (ja) 1991-01-29 1992-09-08 Asahi Chem Ind Co Ltd タンパク質の測定方法、試薬及びキット
JPH04252955A (ja) 1991-01-29 1992-09-08 Asahi Chem Ind Co Ltd 蛋白質の測定方法、試薬及びキット
JPH04252954A (ja) 1991-01-29 1992-09-08 Asahi Chem Ind Co Ltd タンパクの測定方法、試薬及びキット
CA2127450C (en) 1992-01-07 2007-04-17 Samuel Wadsworth Transgenic animal models for alzheimer's disease
US5604102A (en) * 1992-04-15 1997-02-18 Athena Neurosciences, Inc. Methods of screening for β-amyloid peptide production inhibitors
US5837672A (en) 1992-07-10 1998-11-17 Athena Neurosciences, Inc. Methods and compositions for the detection of soluble β-amyloid peptide
US5766846A (en) 1992-07-10 1998-06-16 Athena Neurosciences Methods of screening for compounds which inhibit soluble β-amyloid peptide production
US6610493B1 (en) 1993-06-17 2003-08-26 Brigham And Women's Hospital Screening compounds for the ability to alter the production of amyloid-β peptide
DE69333144T2 (de) 1992-10-26 2004-05-19 Elan Pharmaceuticals, Inc., San Francisco Verfahren zur Identifizierung von Hemmstoffe der Produktion des beta-Amyloidpeptids
EP0683234B2 (en) 1993-01-25 2007-06-06 Takeda Chemical Industries, Ltd. Antibody against beta-amyloid or their derivative and use thereof
US6114133A (en) 1994-11-14 2000-09-05 Elan Pharmaceuticals, Inc. Methods for aiding in the diagnosis of Alzheimer's disease by measuring amyloid-β peptide (x-≧41)
US7427392B1 (en) 1994-11-14 2008-09-23 Elan Pharmaceuticals, Inc. Methods for aiding in the diagnosis of alzheimer's disease by measuring amyloid-β peptide (x-≧41) and tau
US5786180A (en) 1995-02-14 1998-07-28 Bayer Corporation Monoclonal antibody 369.2B specific for β A4 peptide
DE60114157T2 (de) 2000-02-21 2006-06-29 Pharmexa A/S Verfahren zur herabregulierung von amyloid
US20050227941A1 (en) * 2001-12-17 2005-10-13 Karen Duff Sequestration of ass in the periphery in the absence of immunomodulating agent as a therapeutic approach for the treatment or prevention of beta-amyloid related diseases
US7380724B2 (en) 2002-07-01 2008-06-03 Sony Ericsson Mobile Communications Ab Entering text into an electronic communication device
JP4252956B2 (ja) 2002-10-29 2009-04-08 Ｈｏｙａ株式会社 化学強化用ガラス、情報記録媒体用基板、情報記録媒体及び情報記録媒体の製造方法
JP4252954B2 (ja) 2004-12-02 2009-04-08 インターナショナル・ビジネス・マシーンズ・コーポレーション 情報処理装置、情報処理装置のパワーマネージメント方法、およびそのためのプログラム

Also Published As

Publication number Publication date
US20040265920A1 (en) 2004-12-30
CA2205359C (en) 2006-07-04
AU705907B2 (en) 1999-06-03
US7427392B1 (en) 2008-09-23
CA2205359A1 (en) 1996-05-23
ATE278957T1 (de) 2004-10-15
DE69533623T2 (de) 2006-03-02
EP1491889A3 (en) 2005-04-06
JPH10509797A (ja) 1998-09-22
JP3634375B2 (ja) 2005-03-30
US7811769B2 (en) 2010-10-12
PT792458E (pt) 2005-02-28
EP0792458A1 (en) 1997-09-03
EP0792458B1 (en) 2004-10-06
ES2230551T3 (es) 2005-05-01
WO1996015452A1 (en) 1996-05-23
US20040253643A1 (en) 2004-12-16
EP1491889A2 (en) 2004-12-29
US20050069968A1 (en) 2005-03-31
JP2004077499A (ja) 2004-03-11
EP0792458A4 (en) 1999-04-07
US7700309B2 (en) 2010-04-20
DE69533623D1 (de) 2004-11-11
AU4154496A (en) 1996-06-06

Similar Documents

Publication Publication Date Title
DK0792458T3 (da) Fremgangsmåder til hjælp ved diagnosen af Alzheimers sygdom ved måling af amyloid-betapeptid (x->41) og tau
Anderson et al. Proteins of human urine. I. Concentration and analysis by two-dimensional electrophoresis.
NO20050186D0 (no) Oligosakkaridbiomarkorer for mucopolysakkaridoser og andre beslektede forstyrrelser
DK0883371T3 (da) Metode til overvågning af en patients helbred ved måling og forudsigelse af glukoseniveauet i patientens blodprøve
DE69521608D1 (de) Verwendung von humanem neutrophil-lipocalin(hnl) als diagnostischer marker und anti-hnl-antikörperzubereitung
ATE160875T1 (de) Verfahren zum nachweis und/oder zur bestimmung und/oder zur isolierung von apoptotischen zellen in oder aus einer probe
DK1625403T3 (da) Fremgasngsmåde til forudsigelsen, diagnosen og differentialdiagnosen af Alzheimers sygdom
ATE475888T1 (de) Biomarker zur diagnose von alzheimer
Strohmaier et al. Spot urine samples for the metabolic evaluation of urolithiasis patients
WO2001020533A3 (en) Creation of a database of biochemical data and methods of use
EP2126563A1 (en) Method for determining health status by analyzing analytes
Ghomrasseni et al. Morphometric analysis of elastic skin fibres from patients with: cutis laxa, anetoderma, pseudoxanthoma elasticum, and Buschke–Ollendorff and Williams–Beuren syndromes
AU6679501A (en) A method for detecting a lipoprotein-acute phase protein complex and predicting an increased risk of system failure or mortality
ATE189742T1 (de) Test zur diagnose von demenz
JP4583685B2 (ja) 哺乳動物の、特にヒトの受精能を測定する方法
JP4735503B2 (ja) 腹膜機能マーカー、その分析方法およびその用途
Dietrich et al. SPINA-THYR: a novel systems theoretic approach to determine the secretion capacity of the thyroid gland
ATE459877T1 (de) Diagnostikum für die frühe phase von morbus alzheimer
NO20010175L (no) Immunanalyse av humant medullasin og diagnose av multippel sklerose ved den samme
FI951778A0 (fi) Menetelmä allergian toteamiseksi
Anyaiwe Pathology and Neuroimaging for Alzheimer’s Disease
DK166988A (da) Diagnose, alvorlighedsforudsigelse og kontrollering af sygdom ved imunoproevning af frie aktiveringspeptider af pancreatiske zymogener
JPH01169356A (ja) 腎機能検査方法及び装置
RU1804791C (ru) Способ определени функционального состо ни человека
SU888040A1 (ru) Способ диагностики хронического простатита